Ortho Regenerative Technologies has extended its clinical hold on its Ortho-R drug, according to an Aug. 20 news release.
Ortho-R is being studied in rotator cuff tear repair. OrthoRTI plans to enroll 78 patients for its phase 1 and 2 clinical trials in the fall.
The trial was put on hold in June, and OrthoRTI submitted data related to the drug's chemistry, manufacturing and control to the FDA in July.